Skip to main content
Log in

Suppressive antiviral therapy improves quality of life in patients with recurrent genital herpes

  • Pharmacoeconomics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table 2
Table 1

References

  1. Brentjens MH, Yeung-Yue KA, Lee PC, et al. Recurrent genital herpes treatments and their impact on quality of life. Pharmacoeconomics 2003; 21 (12): 853–63.

    Article  PubMed  CAS  Google Scholar 

  2. Taboulet F, Halioua B, Malkin JE. Quality of life and use of health care among people with genital herpes in France. Acta Derm Venereol 1999; 79 (5): 380–4.

    Article  PubMed  CAS  Google Scholar 

  3. Doward LC, McKenna SP, Kohlmann T, et al. The international development of the RGHQoL: a quality of life measure for recurrent genital herpes. Qual Life Res 1998; 7 (2): 143–53.

    Article  PubMed  CAS  Google Scholar 

  4. Centers for Disease Control and Prevention. Diseases characterized by genital ulcers. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2002; 51 (RR-6): 11–25.

    Google Scholar 

  5. Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD). 2002 national guideline for the management of genital herpes [online]. Available from: URL: http://www.agum.org.uk [Accessed 2003 Oct31]

  6. Leung DT, Sacks SL. Current recommendations for the treatment of genital herpes. Drugs 2000; 60 (6): 1329–52.

    Article  PubMed  CAS  Google Scholar 

  7. British National Formulary No. 46 [online]. Available from URL: http://www.bnf.org [Accessed 2003 Nov 21]

  8. Carney O, Ross E, Ikkos G, et al. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes. Genitourin Med 1993; 69 (6): 457–9.

    PubMed  CAS  Google Scholar 

  9. Patel R, Tyring S, Strand A, et al. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999; 75 (6): 398–402.

    Article  PubMed  CAS  Google Scholar 

  10. Romanowski B, Marina RB, Roberts JN, et al. Patients’ preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis 2003; 30 (3): 226–31.

    Article  PubMed  CAS  Google Scholar 

  11. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 121 (11): 847–54.

    PubMed  CAS  Google Scholar 

  12. Patel R, Boselli F, Cairo I, et al. Patients’ perspectives on the burden of recurrent genital herpes. Int J STD AIDS 2001; 12 (10): 640–5.

    Article  PubMed  CAS  Google Scholar 

  13. Mertz GJ, Benedetti J, Ashley R, et al. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116 (3): 197–202.

    PubMed  CAS  Google Scholar 

  14. Corey L, Tyring S, Beutner K, et al. Once daily valaciclovir reduces transmission of genital herpes [abstract LB-3]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2002 Sep 27–30; San Diego

  15. Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999; 131 (1): 14–20.

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suppressive antiviral therapy improves quality of life in patients with recurrent genital herpes. Drugs Ther. Perspect 20, 23–26 (2004). https://doi.org/10.2165/00042310-200420030-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200420030-00008

Keywords

Navigation